Doctors have been treating diabetes with insulin since 1922. A century later, about one in five of the 37 million Americans living with diabetes take this medication—a hormone that helps cells absorb sugar from the blood.
Civica Rx, a nonprofit that manufactures generic drugs, is trying to help solve this problem. It’s planning to produce generic insulin for no more than $30 for a month’s worth of the drug at a factory being built in Petersburg, Va. Eventually the drugmaker intends to sell all three of the most popular kinds of insulin, starting in 2024 with glargine.
Seeing reasons for optimism I’m excited about this initiative because it promises to increase access to all people who require insulin in the U.S., regardless of insurance status or where they buy medications. I’m also optimistic because of support from large insurers as Anthem ANTM, -2.73% and Blue Cross Blue Shield Association for this effort. It’s reassuring that Civica Rx’s leadership includes many people with decades of experience in the pharmaceutical industry and in health policy.First, there have been prior attempts to manufacture generic insulin in the U.S. None have succeeded.
I love the USA and living here is great but after living in the UK and Japan I'm baffled by the healthcare system here. Insurance companies deciding a patient's treatment and medication? It's ludicrous.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
ソース: TheBlock__ - 🏆 464. / 53 続きを読む »